instruction
stringclasses 1
value | input
stringlengths 17
568
| output
stringlengths 1
80
|
|---|---|---|
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | PURPOSE: To present a case of respiratory depression following the administration of nebulised morphine. | Respiratory depression |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in Wilson's disease. | Dystonia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | From these data, acute generalized dystonia with brainstem and thalamic lesions may occur in WD patients after an initial d-penicillamine therapy. | Dystonia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We reported 3 patients who developed acute generalized dystonia and akinetic rigid syndrome following an initial therapy with d-penicillamine 125-500 mg daily. | Dystonia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Ballistic movements due to ischemic infarcts after intravenous heroin overdose: report of two cases. | Ballismus |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Patient 1 presented bilateral ballism 1 week after intravenous heroin injection. | Ballismus |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Stroke is an infrequent but recognized complication of heroin addiction. | Cerebrovascular accident |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Two heroin addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin overdose. | Ballismus |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A MEDLINE search identified all the reported cases of hypersensitivity reactions to cyclosporine. | Hypersensitivity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: case report and review. | Anaphylactic reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | BACKGROUND: Hypersensitivity reactions to cyclosporine are rare. | Hypersensitivity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | CONCLUSIONS: Hypersensitivity reactions to cyclosporine are due to Cremophor EL. | Hypersensitivity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Fortunately, a hypersensitivity reaction to one formulation of cyclosporine does not preclude use of a different formulation. | Hypersensitivity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | METHODS: We report a patient who had an anaphylactic reaction during the intravenous infusion of cyclosporine. | Anaphylactic reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | OBJECTIVE: To investigate the mechanisms involved in hypersensitivity reactions to cyclosporine and determine the feasibility of future cyclosporine use. | Hypersensitivity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The literature search revealed 22 cases of hypersensitivity reaction to cyclosporine. | Hypersensitivity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Prothipendylhydrochloride-induced priapism: case report. | Priapism |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We present the first case of a patient with priapism after oral intake of the phenothiazine prothipendylhydrochloride. | Priapism |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The chemotherapeutics, including vincristine, actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the hepatotoxicity developed. | Hepatotoxicity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We conclude that vincristine and actinomycin D were the cause of this rare from of hepatotoxicity and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery. | Hepatotoxicity |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Because the combination of bleomycin and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop Raynaud's phenomenon under chemotherapy. | Necrosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In this report, one patient who developed gangrene after bleomycin and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented. | Gangrene |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia. | Thrombocytosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Second cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or interferon alfa. | Haematological malignancy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Effect of beta-blockade on symptomatic dexamethasone-induced hypertrophic obstructive cardiomyopathy in premature infants: three case reports and literature review. | Hypertrophic cardiomyopathy |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment, none of which was clinically significant. | Bradycardia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and abdominal cramping on day 6 of therapy with clindamycin vaginal cream for bacterial vaginosis. | Abdominal pain |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Clostridium difficile toxin-induced colitis after use of clindamycin phosphate vaginal cream. | Clostridium difficile colitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | CONCLUSIONS: This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin. | Clostridium difficile colitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | DISCUSSION: No published clinical studies in patients receiving clindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with diarrhea. | Clostridium test positive |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | OBJECTIVE: To report a case of toxin-positive Clostridium difficile-induced colitis (CDIC) after use of clindamycin phosphate vaginal cream. | Clostridium difficile colitis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 54-year-old man developed TEN 4 weeks after beginning lamotrigine for complex partial seizures related to a glioblastoma multiforme brain tumor. | Toxic epidermal necrolysis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Administration of lamotrigine, especially in combination with valproic acid, may lead to the development of TEN. | Toxic epidermal necrolysis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Fatal toxic epidermal necrolysis related to lamotrigine administration. | Toxic epidermal necrolysis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | To date, eight cases of TEN and one of SJS related to lamotrigine administration have been reported in the literature. | SJS-TEN overlap |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A syndrome of increased affect in response to risperidone among patients with schizophrenia. | Affective disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of risperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and insomnia. | Depression |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase. | Inappropriate affect |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 28 year old white schizophrenic male has been under risperidone monotherapy for about one year when he developed dyskinetic movements. | Dyskinesia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Risperidone-induced tardive dyskinesia. | Tardive Dyskinesia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | This report presents a potential case of risperidone-induced tardive dyskinesia. | Tardive Dyskinesia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Increased ocular pressure in two patients with narrow angle glaucoma treated with venlafaxine. | Intraocular pressure increased |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy. | Systemic lupus erythematosus |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Glomerulonephritis in procainamide induced lupus erythematosus: report of a case and review of the literature. | Glomerulonephritis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report a 76-year-old man who developed an acute blistering eruption following high-dose penicillin treatment for pneumococcal septicaemia. | Dermatitis bullous |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A case of prolonged suxamethonium apnoea successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported. | Apnoea |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Suxamethonium apnoea terminated with commercial serumcholinesterase. | Apnoea |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Cardiac arrest associated with sulprostone use during caesarean section. | Cardiac arrest |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest. | Cardiac arrest |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression. | flutamide Drug withdrawal syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Anaphylactic reaction to oral prednisone: a case report and review of the literature. | Anaphylactic reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We describe the case of a nonatopic 17-year-old girl with bronchial asthma and aspirin intolerance who developed a dramatic anaphylactic reaction to oral prednisone. | Anaphylactic reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16, but not with placebo. | Vomiting |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | She was treated with Pancrease MT 16, but had consistent vomiting 1 to 2 hours after administration of enzymes. | Vomiting |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | The vomiting occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and Pancrease MT 16. | Vomiting |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Acute valproate ingestion induces symptomatic methemoglobinemia. | Methaemoglobinaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report for the first time the development of symptomatic methemoglobinemia after an acute ingestion of divalproex sodium (Depakote), resulting in serum concentrations 10 times greater than the therapeutic range. | Methaemoglobinaemia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In rare cases mitomycin C (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure. | Haemolytic anaemia enzyme specific |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Mitomycin C-related hemolytic uremic syndrome in cancer patients. | Haemolytic uraemic syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report a case of MMC-related hemolytic uremic syndrome, and discuss the etiologic parameters, clinical aspects, prognosis and treatment modalities of this severe syndrome. | Haemolytic uraemic syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | CD4 T-lymphocyte depletion, myelosuppression, and subsequent severe infections are the major side effects of fludarabine phosphate therapy. | Lymphocyte count decreased |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia. | Respiratory syncytial virus infection |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report here on a heretofore undescribed respiratory syncytial virus (RSV) infection in a patient with a long-standing history of refractory CLL that was treated with fludarabine phosphate. | Respiratory syncytial virus infection |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports. | Serotonin syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Although this G-CSF-driven leucocytosis was alarming it did not appear to have adversely affected the patient's prognosis. | Leukocytosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Leukaemoid monocytosis in M4 AML following chemotherapy and G-CSF. | Leukaemoid reaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We describe a patient with M4 AML treated with standard chemotherapy followed by G-CSF who developed marked monocytosis on day 8 of G-CSF therapy. | Monocytosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation, t (1;5) (p36;q31) in 90% of the cells. | Autosomal chromosome anomaly |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Chromosome abnormalities after chlorambucil therapy of polycythaemia vera. | Acquired chromosomal abnormality |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Administration of steroid and decreasing the dose of PTU produced a good clinical response and the ANCA disappeared. | Antineutrophil cytoplasmic antibody |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with propylthiouracil therapy. | Antineutrophil cytoplasmic antibody |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A teenage girl with crescentic glomerulonephritis had antineutrophil cytoplasmic antibody (ANCA) detected after she had received propylthiouracil (PTU) for hyperthyroidism without cutaneous vasculitis. | Antineutrophil cytoplasmic antibody |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with PTU appeared to induce ANCA. | Antineutrophil cytoplasmic antibody |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A drug interaction between zafirlukast and theophylline. | Drug interaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Attempts were made to stop and then restart the theophylline therapy at progressively lower doses; however, with each attempt, the patient's reaction to the drug became more toxic, with serum theophylline levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL). | Toxicity to various agents |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We present the first case (to our knowledge) of a potentially serious drug-drug interaction between zafirlukast and theophylline. | Drug interaction |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia. | Rhabdomyolysis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium-activated K+ channels. | Rhabdomyolysis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes. | Rhabdomyolysis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or anticholinergic symptoms with the use of diphenhydramine. | Anticholinergic syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Excluding other causes, Pentasa-associated pancytopenia was considered. | Pancytopenia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | He developed fever, nausea, diarrhea, and malaise and stopped taking on the third day after commencing Pentasa. | Diarrhoea |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn's disease. | Pancytopenia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report a case of pancytopenia in a 23-year-old man with Crohn's disease who was treated with 5-aminosalicylic acid (Pentasa; Nisshin, Tokyo, Japan) 3.0 g/day. | Pancytopenia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess. | Nocardiosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss. | Deafness neurosensory |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | A 47 year-old woman who had a 4-year history of intramuscular pentazocine injections in the lower extremities, developed gradual stiffness and weakness of the lower extremities. | Musculoskeletal stiffness |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy. | Muscle fibrosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Pentazocine-induced fibrous myopathy and localized neuropathy. | Muscle fibrosis |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | In two of these cases akathisia resolved after withdrawal of olanzapine and substitution by a classical or an atypical neuroleptic agent, respectively. | Akathisia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Like other atypical neuroleptics olanzapine is considered to show a reduced prevalence of extrapyramidal side effects when compared to classical neuroleptic drugs. | Extrapyramidal disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | One should therefore be aware of possible extrapyramidal side effects with olanzapine that are reduced compared to classical neuroleptic drugs but not completely eliminated. | Extrapyramidal disorder |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Severe akathisia during olanzapine treatment of acute schizophrenia. | Akathisia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | We report on three patients with acute schizophrenia, who developed severe akathisia during treatment with olanzapine (20-25 mg/d). | Akathisia |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor. | Seizure |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | However, 1 eye had vitreous hemorrhage after repeated injections of tPA. | Vitreous haemorrhage |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | However, repeated intracameral tPA injections may cause unwanted complications such as vitreous hemorrhage. | Vitreous haemorrhage |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Although praziquantel administration may have been effective in killing the parasite in both patients, we are concerned about the production of marked inflammation as a result of treatment. | Inflammation |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | NMS is a drug-related response to various medications, such as Haloperidol, which the patient was receiving. | Neuroleptic malignant syndrome |
Map Adverse Drug Events (ADEs) mentioned in text data to their most relevant Preferred MeDDRA terms. | Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor. | Aplastic Anaemia |